Actively Recruiting
Led by Radboud University Medical Center · Updated on 2026-01-08
360
Participants Needed
19
Research Sites
130 weeks
Total Duration
Researchers are evaluating two diagnostic approaches for patients suspected of having muscle-invasive bladder cancer (MIBC). This trial compares the standard care method, Transurethral Resection of the Bladder Tumor (TURBT), with a newer approach using multiparametric MRI (mpMRI) followed by a same-day cystoscopic bladder biopsy. The study aims to assess progression-free survival, time to definitive treatment, and cost-effectiveness over two years. Participants will be randomly assigned to one of two groups: one undergoing mpMRI plus same-day cystoscopic bladder biopsy, and the other receiving TURBT with blood samples taken shortly before and after the procedure. Both groups will be monitored and compared for their diagnostic outcomes and related healthcare costs. Throughout the study, participants will have regular evaluations including assessments of progression-free survival, quality of life, healthcare costs, and circulating tumor cells before and after TURBT. The main outcome measure is progression-free survival at two years. The study involves multiple centers and aims to provide detailed information on the effectiveness and cost implications of these diagnostic strategies.
CONDITIONS
Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo a multiparametric MRI plus a same-day cystoscopic bladder biopsy or a transurethral resection of the bladder tumor with blood withdrawal before and after the procedure to assess muscle invasive bladder cancer.
1 visit (in-person)
Duration - 2 years
Participants are monitored for progression-free survival, time to definitive treatment, quality of life, healthcare costs, and circulating tumor cells over 2 years after the diagnostic procedures.
Periodic assessments over 2 years
Total: 19 locations
1
Jeroen Bosch ziekenhuis
's-Hertogenbosch, Netherlands
Actively Recruiting
2
Ziekenhuisgroep Twente
Almelo, Netherlands
Actively Recruiting
3
Meander MC
Amersfoort, Netherlands
Not Yet Recruiting
4
Amsterdam UMC, location AMC
Amsterdam, Netherlands
Actively Recruiting
5
Amsterdam UMC, location VUmc
Amsterdam, Netherlands
Actively Recruiting
6
Antoni van Leeuwenhoek - Netherlands Cancer Institute
Amsterdam, Netherlands
Actively Recruiting
7
OLVG
Amsterdam, Netherlands
Actively Recruiting
8
Rijnstate ziekenhuis
Arnhem, Netherlands
Actively Recruiting
9
Maasziekenhuis Pantein
Boxmeer, Netherlands
Actively Recruiting
10
Ziekenhuis Gelderse Vallei
Ede, Netherlands
Actively Recruiting
11
Treant
Emmen, Netherlands
Not Yet Recruiting
12
Medisch Spectrum Twente
Enschede, Netherlands
Not Yet Recruiting
13
St. Antonius ziekenhuis
Nieuwegein, Netherlands
Actively Recruiting
14
Canisius Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Actively Recruiting
15
Radboud university medical center
Nijmegen, Netherlands
Actively Recruiting
16
Erasmus Medical Center
Rotterdam, Netherlands
Not Yet Recruiting
17
Bernhoven ziekenhuis
Uden, Netherlands
Actively Recruiting
18
University Medical Center Utrecht
Utrecht, Netherlands
Actively Recruiting
19
VieCuri medisch centrum
Venlo, Netherlands
Actively Recruiting
A
A. G. van der Heijden, Dr.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sebastiaan W van Koeverden, Lisa Mc van Hoogstraten, Maarten de Rooij...
https://pubmed.ncbi.nlm.nih.gov/40819867